
  
    
      
        Introduction_NNP
        IL-_NNP 10_CD is_VBZ a_DT potent_JJ monocyte_NN /_NN macrophage_NN regulatory_JJ
        cytokine_NN that_IN inhibits_NNS expression_NN of_IN proinflammatory_NN
        mediators_NNS [_NN 1_CD 2_CD ]_NN ._. Monocytes_NNP /_NN macrophages_NNS ,_, B_NNP cells_NNS ,_, murine_NN
        Th_NNP 2_CD cells_NNS ,_, and_CC some_DT CD_NNP 8_CD +_NN cells_NNS produce_VBP IL-_NNP 10_CD [_NN 3_CD 4_CD ]_NN ._.
        Macrophages_NNP rapidly_RB produce_VBP proinflammatory_NN cytokines_NNS such_JJ
        as_IN tumor_NN necrosis_NNS factor_NN alpha_NN (_( TNF-α_NNP )_) ,_, IL-_NNP 1_CD and_CC IL-_NNP 12_CD
        after_IN activation_NN with_IN lipopolysaccharide_NN or_CC IFN-γ_NNP ,_, while_IN
        production_NN of_IN IL-_NNP 10_CD is_VBZ delayed_VBN ._. Once_RB IL-_NNP 10_CD is_VBZ produced_VBN it_PRP
        functions_NNS in_IN an_DT autoregulatory_NN fashion_NN to_TO suppress_VB
        proinflammatory_NN cytokine_NN mRNA_NN expression_NN and_CC protein_NN
        production_NN [_NN 5_CD 6_CD 7_CD ]_NN ._. In_IN addition_NN ,_, IL-_NNP 10_CD suppresses_NNS the_DT
        expression_NN of_IN MHC_NNP class_NN II_NNP molecules_NNS and_CC costimulatory_NN
        molecules_NNS such_JJ as_IN intercellular_NN adhesion_NN molecule_NN 1_CD and_CC B_NNP 7_CD ,_,
        leading_VBG to_TO reduction_NN in_IN T-_NNP cell_NN macrophage_NN interactions_NNS [_NN 8_CD
        9_CD 10_CD ]_NN ._.
        The_DT selective_JJ suppression_NN of_IN Th_NNP 1_CD cell_NN activity_NN is_VBZ
        believed_VBN to_TO be_VB due_JJ to_TO IL-_NNP 10_CD inhibition_NN of_IN IL-_NNP 12_CD ,_, a_DT
        differentiation_NN factor_NN for_IN Th_NNP 1_CD cells_NNS [_NN 11_CD 12_CD ]_NN ._. The_DT
        release_NN of_IN reactive_JJ oxygen_NN and_CC nitrogen_NN intermediates_NNS by_IN
        macrophages_NNS is_VBZ also_RB suppressed_VBN by_IN IL-_NNP 10_CD [_NN 13_CD 14_CD ]_NN ._. In_IN
        addition_NN ,_, IL-_NNP 10_CD stimulates_NNS the_DT production_NN of_IN cytokine_NN
        inhibitors_NNS such_JJ as_IN IL-_NNP 1_CD receptor_NN antagonist_NN [_NN 15_CD ]_NN ._. In_IN
        patients_NNS with_IN rheumatoid_NN arthritis_NN ,_, IL-_NNP 10_CD is_VBZ produced_VBN by_IN
        synovial_NN membrane_NN cells_NNS and_CC is_VBZ found_VBN at_IN high_JJ levels_NNS in_IN the_DT
        synovial_NN fluid_JJ [_NN 16_CD 17_CD ]_NN ._. It_PRP has_VBZ been_VBN shown_VBN that_DT
        suppression_NN of_IN IL-_NNP 10_CD production_NN by_IN synovial_NN cells_NNS is_VBZ
        associated_VBN with_IN increased_VBN levels_NNS of_IN IL-_NNP 1_CD and_CC TNF-α_NNP ,_,
        suggesting_VBG that_IN IL-_NNP 10_CD plays_VBZ a_DT suppressive_JJ role_NN in_IN
        rheumatoid_NN arthritis_NN joints_NNS [_NN 16_CD ]_NN ._. It_PRP was_VBD also_RB observed_VBN
        that_IN IL-_NNP 10_CD directly_RB stimulated_VBN proteoglycan_NN synthesis_NN and_CC
        reversed_VBD the_DT cartilage_NN degradation_NN induced_VBN by_IN activated_VBN
        mononuclear_NN cells_NNS [_NN 18_CD ]_NN ._. These_DT immunosuppressive_JJ
        activities_NNS indicate_VBP that_IN IL-_NNP 10_CD is_VBZ a_DT potential_JJ therapeutic_JJ
        approach_NN for_IN autoimmune_JJ diseases_NNS ._.
        In_IN animal_NN models_NNS of_IN arthritis_NN ,_, systemic_JJ treatment_NN with_IN
        IL-_NNP 10_CD and_CC adenovirus-mediated_JJ transfer_NN of_IN viral_JJ IL-_NNP 10_CD
        moderately_RB suppresses_NNS the_DT development_NN of_IN arthritis_NN ,_, but_CC is_VBZ
        significantly_RB more_RBR effective_JJ when_WRB combined_VBN with_IN IL-_NNP 4_CD [_NN 19_CD
        20_CD 21_CD 22_CD 23_CD 24_CD ]_NN ._. The_DT evidence_NN for_IN the_DT importance_NN of_IN IL-_NNP 10_CD
        is_VBZ further_RBR supported_VBN by_IN the_DT fact_NN that_IN 
        in_IN vivo_NN anti-_NN IL-_NNP 10_CD treatment_NN
        accelerates_VBZ disease_NN in_IN collagen-induced_JJ arthritis_NN (_( CIA_NNP )_) [_NN
        22_CD ]_NN ._.
        Most_JJS studies_NNS focused_VBN on_IN investigating_VBG the_DT role_NN of_IN IL-_NNP 10_CD
        in_IN models_NNS of_IN arthritis_NN have_VBP involved_VBN administration_NN of_IN
        neutralizing_VBG antibodies_NNS ,_, large_JJ amounts_NNS of_IN IL-_NNP 10_CD ,_, or_CC gene_NN
        therapy_NN in_IN experimental_JJ animals_NNS ._. While_IN these_DT studies_NNS are_VBP
        helpful_JJ in_IN broadly_RB defining_VBG the_DT function_NN of_IN IL-_NNP 10_CD ,_, it_PRP is_VBZ
        difficult_JJ to_TO determine_VB the_DT cytokine_NN dose_NN and_CC timing_NN by_IN
        these_DT means_NNS ._. To_TO address_VB the_DT effects_NNS of_IN complete_JJ elimination_NN
        of_IN IL-_NNP 10_CD 
        in_IN vivo_NN on_IN the_DT development_NN of_IN CIA_NNP and_CC
        to_TO understand_VB the_DT mechanism_NN responsible_JJ for_IN IL-_NNP 10_CD
        regulation_NN ,_, we_PRP examined_VBD the_DT development_NN of_IN arthritis_NN in_IN
        homozygous_JJ IL-_NNP 10_CD -_: /_NN -_: IL-_NNP 10_CD -_: deficient_NN mice_NNS ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Animals_NNS ,_, antigens_NNS ,_, and_CC immunization_NN
          procedure_NN
          The_DT IL-_NNP 10_CD -_: /_NN -_: mice_NNS were_VBD generated_VBN as_RB previously_RB
          described_VBD [_NN 25_CD ]_NN ._. The_DT original_JJ genetic_JJ background_NN of_IN
          these_DT animals_NNS was_VBD a_DT mixture_NN of_IN the_DT strains_NNS 129_CD /_NN Ola_NNP and_CC
          C_NNP 57_CD BL_NNP /_NN 6_CD ._. These_DT IL-_NNP 10_CD -_: /_NN -_: mice_NNS were_VBD backcrossed_JJ to_TO DBA_NNP /_NN 1_CD
          for_IN six_CD generations_NNS and_CC further_JJ backcrossed_JJ for_IN an_DT
          additional_JJ two_CD generations_NNS to_TO DBA_NNP /_NN 1_CD (_( Jackson_NNP
          Laboratories_NNPS ,_, Bar_NNP Harbor_NNP ,_, MA_NNP ,_, USA_NNP )_) in_IN our_PRP$ laboratory_NN ._.
          All_DT mice_NNS were_VBD typed_VBN for_IN the_DT IL-_NNP 10_CD mutation_NN by_IN PCR_NNP
          using_VBG primer_NN sets_NNS that_WDT detect_VBP either_DT the_DT DBA_NNP /_NN 1_CD wildtype_NN
          (_( WT_NNP )_) or_CC the_DT mutated_VBN IL-_NNP 10_CD gene_NN ._. In_IN addition_NN ,_, splenocytes_NNS
          from_IN IL-_NNP 10_CD -_: /_NN -_: mice_NNS activated_VBN 
          in_IN vitro_NN did_VBD not_RB produce_VB IL-_NNP 10_CD ._.
          The_DT IL-_NNP 10_CD -_: /_NN -_: mice_NNS were_VBD maintained_VBN in_IN sterilized_VBN
          bedding_NN and_CC food_NN with_IN acidified_VBN water_NN ._. Chicken_NN type_NN II_NNP
          collagen_NN was_VBD used_VBN for_IN generation_NN of_IN arthritis_NN as_IN
          described_VBN elsewhere_RB [_NN 26_CD ]_NN ._. Male_NN and_CC female_JJ WT_NNP ,_,
          heterozygous_JJ IL-_NNP 10_CD +_NN /_NN -_: and_CC IL-_NNP 10_CD -_: /_NN -_: mice_NNS were_VBD immunized_JJ
          once_RB with_IN 100_CD μg_NN chicken_NN type_NN II_NNP collagen_NN emulsified_JJ in_IN
          complete_JJ Freund_NNP 's_POS adjuvant_NN (_( CFA_NNP )_) (_( Difco_NNP ,_, Detroit_NNP ,_, MI_NNP ,_,
          USA_NNP )_) by_IN intradermal_NN injection_NN at_IN the_DT base_NN of_IN the_DT
          tail_NN ._.
        
        
          Assessment_NNP of_IN arthritis_NN
          Animals_NNS were_VBD examined_VBN for_IN the_DT onset_NN of_IN joint_JJ swelling_VBG
          every_DT other_JJ day_NN ._. A_DT standard_JJ scoring_VBG system_NN based_VBN upon_IN
          redness_NNS and_CC swelling_VBG of_IN each_DT paw_NN (_( ranging_VBG from_IN 0_CD to_TO 4_CD for_IN
          each_DT paw_NN ,_, thus_RB resulting_VBG in_IN a_DT possible_JJ maximum_NN severity_NN
          score_NN of_IN 16_CD )_) was_VBD used_VBN for_IN the_DT assessment_NN of_IN disease_NN
          severity_NN ._. Histologic_NNP studies_NNS were_VBD performed_VBN to_TO determine_VB
          the_DT extent_NN of_IN joint_JJ damage_NN ._. At_IN the_DT end_NN of_IN the_DT experiment_NN ,_,
          hind_NN paws_NNS were_VBD dissected_VBN ,_, fixed_VBN ,_, and_CC decalcified_JJ before_IN
          being_VBG embedded_VBN in_IN paraffin_NN ,_, and_CC were_VBD sectioned_JJ at_IN 6_CD μm_NN as_RB
          previously_RB described_VBD [_NN 27_CD ]_NN ._. Sagittal_NNP sections_NNS were_VBD
          stained_JJ with_IN H_NNP &_CC E_NNP ._.
        
        
          Assessment_NNP of_IN cytokine_NN production_NN by_IN spleen_NN cells_NNS
          in_IN vitro_NN
          Spleens_NNP were_VBD obtained_VBN at_IN various_JJ time_NN points_NNS after_IN
          immunization_NN with_IN collagen_NN ._. Single_NNP cell_NN suspensions_NNS were_VBD
          prepared_VBN as_RB previously_RB described_VBD [_NN 28_CD ]_NN ._. Splenocytes_NNP
          (_( 2_CD ._. 0_CD ×_NN 10_CD 6_CD cells_NNS /_NN ml_NN )_) were_VBD incubated_JJ in_IN 24_CD -_: well_RB Falcon_NNP
          plates_NNS (_( Fisher_NNP Scientific_NNP ,_, Pittsburgh_NNP ,_, PA_NNP ,_, USA_NNP )_) in_IN
          RPMI-_NNP 1640_CD media_NNS containing_VBG 7_CD %_NN fetal_JJ bovine_JJ serum_NN (_( Life_NNP
          Technologies_NNPS ,_, Grand_NNP Island_NNP ,_, NY_NNP ,_, USA_NNP )_) ,_, 100_CD U_NNP /_NN ml_NN
          penicillin_NN ,_, 100_CD μg_NN /_NN ml_NN streptomycin_NN ,_, 2_CD mM_NN L-_NNP glutamine_NN ,_, 50_CD
          mM_NN 2_CD -_: ME_NNP ,_, 1_CD mM_NN sodium_NN pyruvate_NN ,_, 0_CD ._. 01_CD mM_NN nonessential_JJ amino_JJ
          acids_NNS ,_, and_CC 10_CD mM_NN HEPES_NNP ._. Cells_NNP were_VBD stimulated_VBN in_IN the_DT
          presence_NN or_CC absence_NN of_IN collagen_NN (_( 100_CD μg_NN /_NN ml_NN )_) ._. IFN-γ_NNP was_VBD
          measured_VBN from_IN day_NN 5_CD supernatant_NN using_VBG the_DT OptEIA_NNP mouse_NN
          cytokine_NN detection_NN system_NN (_( BD_NNP PharMingen_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP ,_,
          USA_NNP )_) ._.
        
        
          Measurement_NNP of_IN immunoglobulin_NN isotypes_NNS
          An_DT ELISA_NNP was_VBD used_VBN to_TO measure_VB isotype-specific_JJ
          antibodies_NNS in_IN serial_NN dilutions_NNS (_( 1_CD :_: 500_CD -_: 1_CD ._. :_: 2500_CD )_) of_IN sera_NN ._.
          ELISA_NNP plates_NNS were_VBD coated_VBN with_IN 1_CD μg_NN chicken_NN type_NN II_NNP
          collagen_NN ._. Collagen-specific_NNP IgG_NNP isotypes_NNS were_VBD detected_VBN
          with_IN peroxidase-labeled_JJ rabbit_NN anti-mouse_JJ IgG_NNP 
          1_CD or_CC IgG_NNP 
          2_CD a_DT (_( Zymed_NNP Laboratories_NNPS ,_, San_NNP Francisco_NNP ,_,
          CA_NNP ,_, USA_NNP )_) ._. Titrated_NNP concentrations_NNS of_IN IgG_NNP 
          1_CD and_CC IgG_NNP 
          2_CD a_DT myeloma_NN proteins_NNS were_VBD used_VBN to_TO
          generate_VB a_DT standard_JJ curve_NN ,_, and_CC the_DT IgGs_NNP were_VBD detected_VBN
          with_IN the_DT same_JJ labeled_VBN rabbit_NN anti-mouse_JJ IgG_NNP 
          1_CD or_CC IgG_NNP 
          2_CD a_DT antiserum_NN ._.
        
        
          Flow_NNP cytometry_NN
          Flow_NNP cytometry_NN was_VBD performed_VBN on_IN freshly_RB isolated_VBN
          spleen_NN cells_NNS ._. Immunofluorescence_NNP staining_VBG of_IN cell_NN surface_NN
          markers_NNS was_VBD performed_VBN using_VBG FITC-labeled_NNP antibodies_NNS
          against_IN CD_NNP 3_CD ,_, B_NNP 220_CD ,_, CD_NNP 11_CD b_SYM ,_, and_CC CD_NNP 11_CD c_SYM (_( BD_NNP PharMingen_NNP )_) ._.
          FITC-labeled_NNP rat_NN IgG_NNP isotypes_NNS were_VBD used_VBN as_IN controls_NNS ._. FcRs_NNP
          were_VBD blocked_VBN using_VBG anti-_NN FcR_NNP antibody_NN (_( 24_CD G_NNP 2_LS )_) ._. Flow_NNP
          cytometric_JJ analysis_NN was_VBD performed_VBN using_VBG a_DT FACS_NNP
          Caliburflow_NNP cytometer_NN utilizing_VBG CELLQuest_NNP software_NN
          (_( Becton_NNP Dickinson_NNP ,_, San_NNP Jose_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
        
        
          Statistical_NNP analysis_NN
          Analysis_NNP of_IN the_DT arthritis_NN score_NN and_CC disease_NN incidence_NN
          at_IN different_JJ time_NN points_NNS were_VBD carried_VBN out_IN using_VBG the_DT
          nonparametric_JJ Mann-_NNP Whitney_NNP U_NNP test_NN ._. Student_NNP 's_POS 
          t_NN test_NN was_VBD used_VBN for_IN statistical_JJ
          analysis_NN of_IN all_DT other_JJ data_NN ._. Analyses_NNS were_VBD performed_VBN using_VBG
          SPSS_NNP software_NN (_( SPSS_NNP ,_, Chicago_NNP ,_, IL_NNP ,_, USA_NNP )_) ._.
        
      
      
        Results_NNS
        
          Augmented_NNP CIA_NNP in_IN DBA_NNP /_NN 1_CD mice_NNS lacking_VBG IL-_NNP 10_CD
          To_TO determine_VB whether_IN IL-_NNP 10_CD functions_NNS as_IN an_DT endogenous_JJ
          inhibitor_NN of_IN inflammatory_JJ arthritis_NN ,_, we_PRP examined_VBD the_DT
          development_NN of_IN disease_NN using_VBG the_DT CIA_NNP model_NN ._. Male_NN and_CC
          female_JJ WT_NNP ,_, IL-_NNP 10_CD +_NN /_NN -_: ,_, and_CC IL-_NNP 10_CD -_: /_NN -_: littermates_NNS were_VBD
          immunized_JJ with_IN collagen_NN in_IN CFA_NNP intradermally_RB ._. Data_NNS from_IN
          the_DT male_JJ and_CC female_JJ mice_NNS were_VBD pooled_VBN because_IN there_EX was_VBD no_DT
          significant_JJ difference_NN between_IN the_DT two_CD groups_NNS ._.
          All_DT mice_NNS succumb_NN to_TO arthritis_NN but_CC the_DT time_NN of_IN onset_NN
          was_VBD somewhat_RB delayed_VBN in_IN the_DT WT_NNP and_CC IL-_NNP 10_CD +_NN /_NN -_: mice_NNS compared_VBN
          with_IN that_DT in_IN the_DT IL-_NNP 10_CD -_: /_NN -_: mice_NNS (_( Fig_NNP ._. 1_LS a_DT )_) ._. Interestingly_RB ,_,
          the_DT number_NN of_IN arthritic_JJ WT_NNP and_CC IL-_NNP 10_CD +_NN /_NN -_: animals_NNS began_VBD to_TO
          recede_VBP after_IN day_NN 35_CD ,_, whereas_IN all_DT IL-_NNP 10_CD -_: /_NN -_: mice_NNS were_VBD still_RB
          arthritic_JJ at_IN the_DT time_NN of_IN termination_NN of_IN the_DT experiments_NNS ,_,
          although_IN with_IN reduced_VBN severity_NN ._. Arthritis_NNP severity_NN in_IN
          IL-_NNP 10_CD -_: /_NN -_: mice_NNS was_VBD significantly_RB exacerbated_VBN in_IN comparison_NN
          with_IN that_DT of_IN WT_NNP or_CC IL-_NNP 10_CD +_NN /_NN -_: mice_NNS (_( Fig_NNP ._. 1_LS b_SYM )_) ._.
          Inflamed_NNP joints_NNS showed_VBD typical_JJ histopathological_JJ
          abnormalities_NNS described_VBD previously_RB (_( synovial_NN
          proliferation_NN ,_, leukocyte_NN infiltration_NN ,_, cartilage_NN and_CC bone_NN
          erosions_NNS )_) [_NN 29_CD 30_CD ]_NN ,_, which_WDT correlated_JJ well_RB with_IN the_DT
          severity_NN of_IN the_DT clinical_JJ symptoms_NNS ._.
          Taken_VBN together_RB ,_, the_DT results_NNS described_VBD demonstrate_VB that_IN
          IL-_NNP 10_CD is_VBZ important_JJ for_IN controlling_VBG disease_NN severity_NN ._.
        
        
          Anticollagen_NNP antibody_NN is_VBZ reduced_VBN in_IN IL-_NNP 10_CD -_: deficient_NN
          mice_NNS
          Induction_NNP of_IN CIA_NNP is_VBZ dependent_JJ on_IN B_NNP cells_NNS ,_, and_CC high_JJ
          doses_NNS of_IN antibodies_NNS are_VBP pathogenic_JJ when_WRB transferred_VBN to_TO
          naïve_NN recipients_NNS [_NN 31_CD ]_NN ._. IL-_NNP 10_CD can_MD affect_VB both_DT the_DT
          viability_NN and_CC the_DT production_NN of_IN immunoglobulin_NN by_IN B_NNP cells_NNS
          [_NN 32_CD 33_CD ]_NN ._. To_TO determine_VB whether_IN the_DT augmentation_NN in_IN CIA_NNP
          correlated_JJ with_IN an_DT alteration_NN in_IN anticollagen_NN antibodies_NNS ,_,
          we_PRP collected_VBD sera_NN from_IN animals_NNS at_IN the_DT time_NN of_IN sacrifice_NN ._.
          Interestingly_RB ,_, IL-_NNP 10_CD -_: /_NN -_: mice_NNS produced_VBN significantly_RB less_JJR
          anticollagen_NN antibody_NN than_IN either_DT WT_NNP or_CC IL-_NNP 10_CD +_NN /_NN -_: mice_NNS
          (_( Fig_NNP ._. 2_LS )_) ._. Both_DT the_DT IgG_NNP 
          1_CD and_CC the_DT IgG_NNP 
          2_CD a_DT isotypes_NNS of_IN anticollagen_NN antibodies_NNS
          were_VBD substantially_RB reduced_VBN ._.
          These_DT results_NNS suggest_VBP that_IN a_DT decrease_NN in_IN anticollagen_NN
          antibody_NN may_MD be_VB the_DT result_NN of_IN a_DT requirement_NN for_IN IL-_NNP 10_CD in_IN
          B-_NNP cell_NN antibody_NN production_NN ._.
        
        
          IFN-γ_NNP levels_NNS are_VBP reduced_VBN in_IN IL-_NNP 10_CD -_: deficient_NN
          mice_NNS
          IFN-γ_NNP production_NN is_VBZ observed_VBN early_RB in_IN
          collagen-immunized_JJ mice_NNS ,_, and_CC progressively_RB increases_VBZ with_IN
          the_DT time_NN of_IN clinical_JJ manifestation_NN of_IN arthritis_NN ._. Although_IN
          the_DT level_NN of_IN IFN-γ_NNP correlates_NNS with_IN disease_NN ,_, IFN-γ_NNP appears_VBZ
          to_TO play_VB a_DT dual_JJ role_NN in_IN disease_NN activity_NN ._. Anti-_NNP IFN-γ_NNP
          treatment_NN early_RB in_IN the_DT course_NN of_IN disease_NN suppresses_NNS
          arthritis_NN ,_, whereas_IN neutralization_NN of_IN IFN-γ_NNP late_RB in_IN
          disease_NN exacerbates_VBZ arthritis_NN ._. In_IN addition_NN ,_, IFN-γ_NNP
          receptor-deficient_JJ mice_NNS exhibit_NN exacerbated_VBD disease_NN [_NN 34_CD
          35_CD ]_NN ._.
          We_PRP were_VBD therefore_RB interested_JJ in_IN determining_VBG whether_IN
          the_DT levels_NNS of_IN IFN-γ_NNP correlated_JJ with_IN arthritis_NN in_IN
          collagen-immunized_JJ WT_NNP ,_, IL-_NNP 10_CD +_NN /_NN -_: ,_, and_CC IL-_NNP 10_CD -_: /_NN -_: mice_NNS ._.
          Splenocytes_NNP were_VBD isolated_VBN from_IN immunized_JJ mice_NNS and_CC
          cultured_JJ in_IN the_DT presence_NN and_CC absence_NN of_IN collagen_NN (_( Fig_NNP ._.
          3_LS )_) ._. IFN-γ_NNP levels_NNS were_VBD significantly_RB suppressed_VBN in_IN the_DT
          IL-_NNP 10_CD -_: /_NN -_: mice_NNS in_IN comparison_NN with_IN either_DT WT_NNP or_CC IL-_NNP 10_CD
          +_NN /_NN -_: animals_NNS ._.
          These_DT results_NNS confirm_VBP that_WDT reduced_VBD levels_NNS of_IN IFN-γ_NNP
          were_VBD associated_VBN with_IN exacerbated_VBN arthritis_NN in_IN
          collagen-immunized_JJ animals_NNS ._. These_DT data_NNS also_RB suggest_VBP that_IN
          IL-_NNP 10_CD positively_RB regulates_VBZ IFN-γ_NNP ,_, either_CC directly_RB or_CC
          indirectly_RB ._.
        
        
          CD_NNP 11_CD b_SYM +_NN expansion_NN correlates_NNS with_IN reduced_VBN
          IL-_NNP 10_CD
          Matthys_NNP 
          et_CC al_NN ._. recently_RB showed_VBD that_IN the_DT
          enhanced_JJ severity_NN of_IN CIA_NNP in_IN IFN-γ_NNP receptor-deficient_JJ mice_NNS
          immunized_JJ with_IN type_NN II_NNP collagen_NN in_IN CFA_NNP is_VBZ due_JJ to_TO an_DT
          expansion_NN of_IN the_DT CD_NNP 11_CD b_SYM +_NN cells_NNS [_NN 36_CD ]_NN ._. Since_IN IL-_NNP 10_CD
          -_: /_NN -_: mice_NNS produce_VBP reduced_VBN levels_NNS of_IN IFN-γ_NNP ,_, we_PRP were_VBD
          interested_JJ in_IN determining_VBG whether_IN there_EX was_VBD a_DT specific_JJ
          expansion_NN of_IN CD_NNP 11_CD b_SYM +_NN cells_NNS ._.
          Although_IN the_DT spleen_NN cell_NN number_NN increased_VBD in_IN IL-_NNP 10_CD
          -_: /_NN -_: mice_NNS (_( 1_CD ._. 42_CD ×_NN 10_CD 8_CD ±_NN 0_CD ._. 17_CD )_) in_IN comparison_NN with_IN WT_NNP mice_NNS
          (_( 0_CD ._. 84_CD ×_NN 10_CD 8_CD ±_NN 0_CD ._. 23_CD )_) ,_, there_EX was_VBD a_DT specific_JJ expansion_NN of_IN
          the_DT CD_NNP 11_CD b_SYM +_NN cell_NN population_NN ._. The_DT spleen_NN from_IN WT_NNP mice_NNS
          contained_VBD 10_CD ._. 7_CD %_NN CD_NNP 11_CD b_SYM +_NN cells_NNS ,_, whereas_IN the_DT spleen_NN of_IN IL-_NNP 10_CD
          -_: /_NN -_: mice_NNS contained_VBD 22_CD ._. 5_LS %_NN CD_NNP 11_CD b_SYM +_NN cells_NNS (_( Table_NNP 1_LS )_) ._. When_WRB the_DT
          percentage_NN of_IN cells_NNS was_VBD corrected_VBN for_IN cell_NN number_NN ,_, there_EX
          was_VBD a_DT 3_CD ._. 7_CD -_: fold_VB increase_NN in_IN CD_NNP 11_CD b_SYM +_NN cells_NNS in_IN the_DT spleen_NN of_IN
          IL-_NNP 10_CD -_: /_NN -_: mice_NNS ._. The_DT net_JJ number_NN of_IN T_NN cells_NNS ,_, B_NNP cells_NNS ,_, and_CC
          dendritic_JJ cells_NNS was_VBD not_RB significantly_RB different_JJ ._.
          These_DT data_NNS are_VBP consistent_JJ with_IN the_DT inhibitory_NN effects_NNS
          of_IN IFN-γ_NNP on_IN expansion_NN of_IN CD_NNP 11_CD b_SYM +_NN cells_NNS ._. The_DT data_NNS suggest_VBP
          that_IN IL-_NNP 10_CD is_VBZ important_JJ for_IN controlling_VBG IFN-γ_NNP and_CC /_NN or_CC
          other_JJ cytokines_NNS involved_VBN in_IN the_DT process_NN of_IN CD_NNP 11_CD b_SYM +_NN cell_NN
          expansion_NN ._.
          In_IN an_DT attempt_NN to_TO understand_VB the_DT mechanism_NN responsible_JJ
          for_IN the_DT expansion_NN of_IN CD_NNP 11_CD b_SYM +_NN macrophages_NNS in_IN IL-_NNP 10_CD -_: /_NN -_: mice_NNS ,_,
          we_PRP examined_VBD cytokines_NNS associated_VBN with_IN inflammation_NN and_CC
          Th_NNP 1_CD cell_NN phenotype_NN ._. We_PRP were_VBD unable_JJ to_TO detect_VB any_DT
          difference_NN in_IN the_DT IL-_NNP 12_CD or_CC TNF-α_NNP levels_NNS in_IN IL-_NNP 10_CD -_: /_NN -_: mice_NNS
          in_IN comparison_NN with_IN WT_NNP mice_NNS ._. However_RB ,_, IL-_NNP 1_CD β_NN was_VBD
          significantly_RB increased_VBN in_IN IL-_NNP 10_CD -_: /_NN -_: animals_NNS (_( Fig_NNP ._. 4_LS )_) ._.
          These_DT results_NNS suggest_VBP the_DT possibility_NN that_IN IL-_NNP 1_CD β_NN may_MD
          play_VB a_DT role_NN in_IN CD_NNP 11_CD b_SYM +_NN cell_NN expansion_NN ._.
        
      
      
        Discussion_NNP
        IL-_NNP 10_CD appears_VBZ to_TO play_VB an_DT important_JJ role_NN in_IN the_DT
        regulation_NN of_IN several_JJ autoimmune_JJ disease_NN models_NNS ._. Treatment_NNP
        with_IN recombinant_JJ IL-_NNP 10_CD in_IN CIA_NNP ,_, in_IN proteoglycan-induced_JJ
        arthritis_NN ,_, and_CC in_IN experimental_JJ autoimmune_JJ encephalomyelitis_NNS
        reduced_VBD disease_NN severity_NN ,_, and_CC neutralizing_VBG IL-_NNP 10_CD with_IN
        antibodies_NNS exacerbated_VBD disease_NN [_NN 19_CD 20_CD 22_CD 23_CD ]_NN ._. The_DT
        present_JJ data_NN are_VBP consistent_JJ with_IN previous_JJ results_NNS and_CC show_NN
        that_IN a_DT complete_JJ absence_NN of_IN IL-_NNP 10_CD exacerbates_VBZ inflammation_NN
        in_IN CIA_NNP [_NN 37_CD 38_CD 39_CD ]_NN ._. The_DT anti-inflammatory_JJ properties_NNS of_IN
        IL-_NNP 10_CD suggest_VBP that_IN endogenous_JJ IL-_NNP 10_CD may_MD function_VB as_IN a_DT
        regulator_NN of_IN proinflammatory_NN mediators_NNS 
        in_IN vivo_NN [_NN 39_CD ]_NN ._. It_PRP is_VBZ interesting_JJ ,_,
        however_RB ,_, that_DT disease_NN severity_NN inversely_RB correlates_NNS with_IN
        the_DT levels_NNS of_IN IFN-γ_NNP in_IN IL-_NNP 10_CD -_: /_NN -_: mice_NNS ,_, suggesting_VBG that_IN IL-_NNP 10_CD
        may_MD control_VB disease_NN activity_NN via_IN regulating_VBG IFN-γ_NNP
        responses_NNS ._.
        Although_IN CIA_NNP is_VBZ considered_VBN a_DT Th_NNP 1_CD -_: type_NN disease_NN mediated_JJ
        by_IN IFN-γ_NNP ,_, the_DT role_NN of_IN IFN-γ_NNP in_IN the_DT pathogenesis_NNS of_IN CIA_NNP is_VBZ
        not_RB clearly_RB understood_VBN ._. IFN-γ_NNP appears_VBZ to_TO have_VB two_CD separate_JJ
        functions_NNS ,_, disease_NN promoting_VBG as_RB well_RB as_IN disease_NN limiting_VBG [_NN
        40_CD ]_NN ._. Neutralization_NNP of_IN IFN-γ_NNP with_IN antibodies_NNS early_RB in_IN the_DT
        course_NN of_IN disease_NN exerts_NNS a_DT suppressive_JJ effect_NN ,_, whereas_IN
        anti-_NN IFN-γ_NNP treatment_NN late_RB in_IN disease_NN enhances_VBZ arthritis_NN [_NN
        41_CD ]_NN ._. Also_RB ,_, disease_NN severity_NN in_IN CIA_NNP is_VBZ enhanced_VBN in_IN IFN-γ_NNP
        receptor-deficient_JJ mice_NNS ,_, and_CC loss_NN of_IN the_DT IFN-γ_NNP receptor_NN
        turns_VBZ mice_NNS normally_RB resistant_JJ to_TO CIA_NNP into_IN an_DT
        arthritis-susceptible_JJ strain_NN [_NN 34_CD 35_CD ]_NN ._. IFN-γ_NNP thus_RB
        provides_VBZ a_DT dominant_JJ protective_JJ effect_NN in_IN CIA_NNP ._. The_DT reduction_NN
        in_IN IFN-γ_NNP in_IN IL-_NNP 10_CD -_: deficient_NN mice_NNS is_VBZ consistent_JJ with_IN the_DT
        disease-limiting_JJ properties_NNS of_IN IFN-γ_NNP ._. These_DT results_NNS suggest_VBP
        that_IN IL-_NNP 10_CD plays_VBZ an_DT unexpected_JJ role_NN in_IN regulating_VBG IFN-γ_NNP
        production_NN in_IN CIA_NNP ._.
        Recent_JJ work_NN by_IN Matthys_NNP 
        et_CC al_NN ._. demonstrates_VBZ that_IN the_DT
        protective_JJ effect_NN of_IN IFN-γ_NNP is_VBZ dependent_JJ on_IN the_DT presence_NN of_IN
        the_DT mycobacterial_NN component_NN of_IN the_DT adjuvant_NN [_NN 36_CD ]_NN ._. Only_RB
        when_WRB mice_NNS are_VBP immunized_JJ with_IN collagen_NN in_IN CFA_NNP is_VBZ there_EX an_DT
        increase_NN in_IN disease_NN severity_NN in_IN IFN-γ_NNP receptor-deficient_JJ
        mice_NNS ._. Ablation_NNP of_IN IFN-γ_NNP in_IN these_DT mice_NNS is_VBZ associated_VBN with_IN
        extramedullary_JJ hemopoiesis_NNS and_CC expansion_NN of_IN CD_NNP 11_CD b_SYM +_NN cells_NNS ._.
        Consistent_NNP with_IN this_DT observation_NN ,_, a_DT similar_JJ increase_NN in_IN
        CD_NNP 11_CD b_SYM +_NN cells_NNS was_VBD observed_VBN in_IN the_DT IL-_NNP 10_CD -_: /_NN -_: mice_NNS ._. These_DT data_NNS
        suggest_VBP that_IN IL-_NNP 10_CD controls_NNS the_DT IFN-γ_NNP concentration_NN 
        in_IN vivo_NN and_CC that_IN the_DT reduced_VBN level_NN of_IN
        IFN-γ_NNP in_IN IL-_NNP 10_CD -_: /_NN -_: mice_NNS contributes_VBZ to_TO expansion_NN of_IN CD_NNP 11_CD b_SYM
        +_NN cells_NNS and_CC increase_NN in_IN disease_NN severity_NN ._. The_DT increase_NN in_IN
        IL-_NNP 1_CD β_NN we_PRP observed_VBD in_IN IL-_NNP 10_CD -_: /_NN -_: mice_NNS may_MD account_VB for_IN the_DT
        increase_NN in_IN CD_NNP 11_CD b_SYM +_NN cells_NNS as_IN IL-_NNP 1_CD β_NN is_VBZ known_VBN for_IN its_PRP$
        hematopoietic_JJ properties_NNS [_NN 42_CD ]_NN ._.
        In_IN addition_NN to_TO the_DT cellular_JJ immune_JJ response_NN ,_,
        anticollagen_NN antibodies_NNS are_VBP required_VBN for_IN the_DT development_NN of_IN
        arthritis_NN ._. In_IN the_DT studies_NNS presented_VBN ,_, despite_IN the_DT increase_NN
        in_IN disease_NN severity_NN in_IN the_DT IL-_NNP 10_CD -_: /_NN -_: mice_NNS ,_, anticollagen_NN
        antibodies_NNS are_VBP reduced_VBN ._. This_DT reduction_NN in_IN antibody_NN levels_NNS
        may_MD be_VB a_DT direct_JJ effect_NN on_IN B_NNP cells_NNS due_JJ to_TO a_DT loss_NN of_IN IL-_NNP 10_CD or_CC
        may_MD be_VB an_DT indirect_JJ effect_NN due_JJ to_TO downregulation_NN by_IN IFN-γ_NNP ._.
        The_DT Th_NNP 1_CD cytokine_NN IFN-γ_NNP is_VBZ important_JJ 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN for_IN enhancement_NN of_IN IgG_NNP 
        2_CD a_DT secretion_NN [_NN 43_CD ]_NN ._. It_PRP is_VBZ expected_VBN
        that_DT loss_NN of_IN IFN-γ_NNP should_MD result_VB in_IN a_DT reduced_VBN
        collagen-specific_JJ IgG_NNP 
        2_CD a_DT response_NN ,_, but_CC it_PRP is_VBZ unexpected_JJ that_IN
        the_DT IgG_NNP 
        1_CD response_NN would_MD also_RB be_VB reduced_VBN ._. These_DT
        results_NNS indicate_VBP that_IN IL-_NNP 10_CD has_VBZ a_DT direct_JJ effect_NN on_IN
        maintaining_VBG antibody_NN production_NN in_IN CIA_NNP ._. In_IN addition_NN ,_, loss_NN
        of_IN the_DT anti-inflammatory_JJ effect_NN of_IN IL-_NNP 10_CD appears_VBZ to_TO
        overdrive_JJ the_DT requirements_NNS for_IN high_JJ levels_NNS of_IN anticollagen_NN
        antibodies_NNS in_IN CIA_NNP ._.
      
      
        Conclusion_NNP
        In_IN summary_NN ,_, these_DT results_NNS suggest_VBP that_IN IL-_NNP 10_CD is_VBZ an_DT
        important_JJ regulator_NN of_IN inflammation_NN 
        in_IN vivo_NN ._. In_IN CIA_NNP ,_, a_DT deficiency_NN in_IN
        IL-_NNP 10_CD leads_VBZ to_TO an_DT increase_NN in_IN disease_NN severity_NN ._. The_DT
        corresponding_JJ reduction_NN in_IN IFN-γ_NNP levels_NNS and_CC the_DT expansion_NN
        of_IN CD_NNP 11_CD b_SYM +_NN cells_NNS suggests_VBZ a_DT potential_JJ mechanism_NN for_IN IL-_NNP 10_CD
        regulation_NN of_IN CIA_NNP ._.
      
      
        Abbreviations_NNP
        CFA_NNP =_SYM complete_JJ Freund_NNP 's_POS adjuvant_NN ;_: CIA_NNP =_SYM collagen-induced_JJ
        arthritis_NN ;_: ELISA_NNP =_SYM enzyme-linked_JJ immunosorbent_NN assay_NN ;_: FACS_NNP
        =_SYM fluorescence-activated_JJ cell_NN sorting_VBG ;_: FITC_NNP =_SYM fluorescein_NN
        isothiocyanate_NN ;_: H_NNP &_CC E_NNP =_SYM hematoxylin_NN and_CC eosin_NN ;_: IFN_NNP =_SYM
        interferon_NN ;_: IL_NNP =_SYM interleukin_NN ;_: MHC_NNP =_SYM major_JJ
        histocompatibility_NN complex_JJ ;_: PCR_NNP =_SYM polymerase_NN chain_NN
        reaction_NN ;_: Th_NNP cells_NNS =_SYM T_NN helper_NN cells_NNS ;_: TNF-α_NNP =_SYM tumor_NN necrosis_NNS
        factor_NN alpha_NN ;_: WT_NNP =_SYM DBA_NNP /_NN 1_CD wildtype_NN ._.
      
    
  
